ConductScience.org, home

Paper42903486PubMed

Boosting CAR-T cell therapy with CRISPR technology.

Yan L and 5 others. Hlife, 2024.

Cite this record

ConductScience Library. Boosting CAR-T cell therapy with CRISPR technology. Papers, record 42903486. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42903486

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Boosting CAR-T cell therapy with CRISPR technology.
Journal
Hlife
Year
2024
Publication types
Journal Article, Review
Revised in PubMed
2026-10-23

Source PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yan LLiyanran
2Gao SShanzi
3Wang XXinhui
4Zhou XXintao
5Limsakul PPraopim
6Wu YYiqian

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References188

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130804938CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.Front Immunol2019https://conductscience.org/library/papers/30804938PubMed
234218353Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.Curr Med Sci2021https://conductscience.org/library/papers/34218353PubMed
337980345Genome-wide CRISPR off-target prediction and optimization using RNA-DNA interaction fingerprints.Nat Commun2023https://conductscience.org/library/papers/37980345PubMed
422592077The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells.J Exp Clin Cancer Res2012https://conductscience.org/library/papers/22592077PubMed
529385370Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29385370PubMed
631953246Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.Cancer Immunol Res2020https://conductscience.org/library/papers/31953246PubMed
738658804Tonic-ing emissions and compatibility to turbocharge CAR-T.Nat Metab2024https://conductscience.org/library/papers/38658804PubMed
834035409Base-edited CAR T cells for combinational therapy against T cell malignancies.Leukemia2021https://conductscience.org/library/papers/34035409PubMed
931391096PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity.J Immunother Cancer2019https://conductscience.org/library/papers/31391096PubMed
1026738796Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies.Sci Transl Med2016https://conductscience.org/library/papers/26738796PubMed
1137945901Transcriptional and epigenetic regulators of human CD8+ T cell function identified through orthogonal CRISPR screens.Nat Genet2023https://conductscience.org/library/papers/37945901PubMed
1229414259CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions.Annu Rev Med2018https://conductscience.org/library/papers/29414259PubMed
1337041195Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing.Nat Commun2023https://conductscience.org/library/papers/37041195PubMed
1421739672T cell exhaustion.Nat Immunol2011https://conductscience.org/library/papers/21739672PubMed
1524876563Current concepts in the diagnosis and management of cytokine release syndrome.Blood2014https://conductscience.org/library/papers/24876563PubMed
1630941126Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.Front Immunol2019https://conductscience.org/library/papers/30941126PubMed
1736972454Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion.Proc Natl Acad Sci U S A2023https://conductscience.org/library/papers/36972454PubMed
1833907185CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy.Cell Discov2021https://conductscience.org/library/papers/33907185PubMed
1924553386Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.Sci Transl Med2014https://conductscience.org/library/papers/24553386PubMed
2037192099Discovery of Diverse CRISPR-Cas Systems and Expansion of the Genome Engineering Toolbox.Biochemistry2023https://conductscience.org/library/papers/37192099PubMed

See all 188 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first.

PMIDTitleJournalYearIn Papers
41015605Engineering adoptive cell therapy for solid tumors.Med Oncol2025https://conductscience.org/library/papers/41015605

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42903486

GET https://conductscience.org/api/papers/v1/42903486/references?page=2